According to the latest report by IMARC Group, titled “Progressive Familial Intrahepatic Cholestasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033,” the global progressive familial intrahepatic cholestasis market size is witnessing steady growth. Progressive familial intrahepatic cholestasis (PFIC) is a rare genetic medical disorder that affects the ability of the liver to transport bile. It is generally present during infancy or childhood, which can lead to liver failure and cirrhosis. It is associated with different symptoms depending on the type and severity, such as jaundice, itching, abdominal pain, slow weight gain, enlarged liver and spleen, pale or clay colored stool, and dark urine. It is diagnosed through various blood tests, ultrasound, magnetic resonance imaging (MRI) tests, and genetic testing to measure liver function, identify the specific genetic mutation causing the condition, and evaluate the overall function of the liver. It can be treated by doing liver transplantation and using medications, such as ursodeoxycholic acid, which aids in improving bile flow, reducing itching, and preventing liver failure.
Global Progressive Familial Intrahepatic Cholestasis Market Trends:
The surging prevalence of genetic abnormalities among individuals and increasing number of patients suffering from PFIC represent one of the major factors augmenting the market growth around the world. Moreover, the rising adoption of biliary diversion surgery for patients with PFIC type 1 or type 2 who do not respond to medical management is favoring the growth of the market. In addition, significant improvements in the healthcare infrastructure and diagnostic technologies are strengthening the growth of the market. Furthermore, the genetic testing enables physicians to identify specific genetic mutations responsible for the condition and help them tailor the prevention strategies for the patients is contributing to the market growth. Apart from this, there is a rise in the number of clinical trials that are sponsored and funded by numerous government agencies, institutions, hospitals, physicians, pharmaceutical and biotechnology companies, and advocacy groups to perform for the expansion of medications to combat PFIC. This, along with the growing awareness about PFIC disease, its symptoms, diagnosis, and the easy availability of the treatment options, is creating a positive outlook for the market.
- Region-wise, the market has been classified into the United States, EU5 (Germany, France, United Kingdom, Italy, Spain), and Japan.
- This research study also offers a thorough overview of late-stage pipeline candidates and currently marketed medications for progressive familial intrahepatic cholestasis.
- The study also offers a thorough overview of the treatment practices for progressive familial intrahepatic cholestasis, the share of specific therapies, and the performance of key market players.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800